小分子多肽免疫抑制剂PET探针引导肿瘤免疫治疗新进展
PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy
蒋金泉 1刘特立 1夏雷 1朱华 1杨志1
作者信息
- 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- 折叠
摘要
靶向程序性死亡蛋白-1及其配体(PD-1/PD-L1)的免疫抑制剂是目前实体肿瘤免疫治疗的研究热点.通过分子影像方法检测实体肿瘤患者体内PD-1/PD-L1表达情况能够预测肿瘤患者能否从免疫治疗中获益.小分子多肽抑制剂具有相对分子质量低、在肿瘤微环境中扩散速度快、分布均匀、容易到达实体肿瘤深部等显著优势.通过放射性核素标记小分子多肽抑制剂的分子探针PET显像,能够非侵入性、实时、定量地检测肿瘤患者体内PD-1/PD-L1表达,有望为患者筛选、疗效监测、治疗方案优化、预后评估提供新的检测手段.
Abstract
Immunosuppressant targeting programmed death protein-1 and its ligand (PD-1/PD-L1) is a hot topic in solid tumor immunotherapy.Detection of PD-1/PD-L1 expression in solid tumor patients by molecular imaging can predict whether tumor patients can benefit from immunotherapy.Small molecular polypeptide inhibitors have the advantages of low molecular weight,fast diffusion in tumor microenvironment,uniform distribution and easy access to the deep part of solid tumor.Non-invasive,real-time and quantitative detection of PD-1/PD-L1 expression in tumor patients can be performed by radionuclide labeled small molecular polypeptide inhibitor molecular probe PET imaging.It is expected to provide new detection methods for patient screening,efficacy monitoring,treatment plan optimization and prognosis evaluation.
关键词
免疫抑制剂/正电子发射断层显像术/免疫疗法Key words
Immunosuppressive agents/Positron-emission tomography/Immunotherapy引用本文复制引用
基金项目
国家自然科学基金(81401467)
国家自然科学基金(81671733)
出版年
2019
NETL
NSTL
维普
万方数据